Abstract

A method for targeting magnetic particles in a multi-branch blood vessel, according to the present invention, may include the steps of: obtaining a blood vessel path in a multi-branch blood vessel; determining a movement path from an injection point of magnetic particles to a target point; determining a magnetic field-free region (FFR) around at least one blood vessel branch present on the movement path; and injecting magnetic particles into the injection point and moving the magnetic particles to the target point by using the magnetic field generated in the magnetic FFR.

IPC Classes  ?

• A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
• A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
• A61N 2/00 - Magnetotherapy
• A61N 2/02 - Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets

Abstract

Disclosed is a system for experimenting a whisker stimulation-based animal cognitive behavior, enabling an intelligence experiment in which an experimental animal can navigate a path through whisker recognition, and animal training through whisker-based sensing ability. According to an embodiment of the present invention, the system for experimenting a whisker stimulation-based animal cognitive behavior may comprise: a plurality of movement passages of the experimental animal, coupled to form a shape similar to an overall shape of an athletic track; and a whisker stimulation device forming a side wall of the movement passage so as to have preset roughness.

IPC Classes  ?

• A01K 1/03 - Housing for domestic or laboratory animals
• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
• A01K 29/00 - Other apparatus for animal husbandry
• G01D 21/02 - Measuring two or more variables by means not covered by a single other subclass
• H04N 7/18 - Closed-circuit television [CCTV] systems, i.e. systems in which the video signal is not broadcast
• G06N 20/00 - Machine learning

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating bone diseases, and more specifically, includes a TCP-(MP)-Caffeic acid analogue, and thus can inhibit osteoclast differentiation and/or generation and exhibit an excellent prevention or treatment effect on various bone diseases including osteoporosis and the like.

IPC Classes  ?

• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives

Abstract

The present invention provides a sample treatment method for cancer diagnosis, and a method for providing information about cancer diagnosis by using the method. Therefore, information that is helpful for early diagnosis of cancer and monitoring whether cancer recurs after treatment can be provided.

IPC Classes  ?

• G01N 1/36 - Embedding or analogous mounting of samples
• G01N 1/30 - StainingImpregnating
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a lactic acid bacteria formulation capable of healing wounds, comprising a Lactobacillus reuteri NCHBL-005 strain as an active ingredient. Specifically, a Lactobacillus reuteri NCHBL-005 strain, which is one of lactic acid bacteria formulations having a positive effect on the body, is cultured, and the Lactobacillus reuteri NCHBL-005 strain which can be safely used in the human body without toxicity and side effects can be used as a therapeutic formulation. More specifically, as a result of inducing a wound in a mouse fibroblast cell line by using a pipette tip and treating same with a Lactobacillus reuteri NCHBL-005 strain, it was confirmed that the migration and proliferation ability of the cell line was promoted, resulting in rapid wound recovery. The Lactobacillus reuteri NCHBL-005 strain was confirmed to promote the phosphorylation of p38 MAPK, ERK, and JNK, which are protein kinases involved in cell migration and proliferation ability and to promote wound healing in a manner dependent thereon. It was also confirmed that, when a wound was induced in the skin of a mouse and a wound site was directly treated with the Lactobacillus reuteri NCHBL-005 strain, wound healing was promoted compared to an untreated group.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
• A61Q 19/00 - Preparations for care of the skin
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics

Abstract

In a method of preparing lithium hydroxide, a mixture of low-purity lithium carbonate and barium hydroxide is heat-treated, the resulting product obtained through the heat treatment is leached by adding water to form a first slurry including an aqueous lithium hydroxide solution and an insoluble by-product, the first slurry is filtered to separate the lithium hydroxide solution and the insoluble by-product, and the lithium hydroxide solution separated through the filtering of the first slurry is evaporated, thereby obtaining lithium hydroxide.

IPC Classes  ?

• C01D 15/02 - OxidesHydroxides

Abstract

The present invention relates to: an anti-inflammatory or immune-enhancing composition comprising, as an active ingredient, pear pomace powder that is treated with a complex enzyme comprising cellulase, β-glucanase, and xylanase; and a method for preparing same. Therefore, the anti-inflammatory or immune-enhancing composition of the present invention can improve inflammation and exhibit an immune-enhancing effect by activation of the NF-κB signaling pathway.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 29/00 - Foods or foodstuffs containing additivesPreparation or treatment thereof
• A61K 36/73 - Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present invention relates to coated metal stents, to methods for coating or producing such coated metal stents, and to their use in medicine In particular, the present invention relates to metal stents coated with Substance P., to methods for coating or producing such coated stents, and to their use as implants.

IPC Classes  ?

• A61L 31/10 - Macromolecular materials
• A61L 31/02 - Inorganic materials
• A61L 31/16 - Biologically active materials, e.g. therapeutic substances

Abstract

The present invention relates to a composition for improving gut health, comprising, as an active ingredient, pear pomace powder enzyme-treated with a complex enzyme comprising cellulase, beta-glucanase, and xylanase, and a method for preparing same. Accordingly, a food composition for improving gut health and a pharmaceutical composition for preventing or treating gut diseases of the present invention solubilize dietary fiber of pear pomace through an enzymatic reaction, and in particular, prepare dietary fiber rich in hemicellulose, increase solubility, moisture retention, maintenance retention, swelling power, and cholesterol adsorption power, promote gut beneficial bacteria proliferation, and inhibit harmful bacteria proliferation, thereby improving gut health and preventing or treating gut diseases.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 29/00 - Foods or foodstuffs containing additivesPreparation or treatment thereof
• A61K 36/73 - Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

A particle separating apparatus and a method of separating particles using the same are provided. The particle separating apparatus comprises a base part, a micro channel disposed in the base part, an inlet portion disposed at an end portion of the micro channel, wherein light-emitting elements, Newtonian fluid and viscoelastic fluid are injected into the inlet portion, an inlet flow path connecting the inlet portion and the micro channel, an outlet portion disposed at an opposite end portion of the micro channel, wherein the light-emitting elements, the Newtonian fluid and the viscoelastic fluid are discharged from the outlet portion, an outlet flow path connecting the micro channel and the outlet portion, and a vortex generator disposed under the inlet portion to generate a surface acoustic wave.

IPC Classes  ?

• B01D 21/26 - Separation of sediment aided by centrifugal force
• B01D 21/24 - Feed or discharge mechanisms for settling tanks
• B01D 21/28 - Mechanical auxiliary equipment for acceleration of sedimentation, e.g. by vibrators or the like
• B04C 3/00 - Apparatus in which the axial direction of the vortex remains unchanged
• B04C 3/06 - Construction of inlets or outlets to the vortex chamber

Abstract

The present invention relates to a pressure vessel having an outer shell-inner frame structure and a manufacturing method therefor. The pressure vessel having an outer shell-inner frame structure comprises: an outer shell formed as an external polyhedron having, on each of the width, length, and height thereof, a plurality of spherical or hemispherical protrusions arranged regularly and in close contact with each other, and having formed therein a space for storage of fluid; and an inner frame disposed in the inner space of the outer shell and coupled to the outer shell to support the outer shell. Therefore, according to the present invention, high pressure may be withstood using a thin film, which is an advantage of a shellular-type pressure vessel, and any external shape may be provided, safety may be maintained by leakage before rupture, and the manufacturing process for a vessel may be simplified.

IPC Classes  ?

• F16J 12/00 - Pressure vessels in general
• F17C 1/00 - Pressure vessels, e.g. gas cylinder, gas tank, replaceable cartridge
• B21D 13/10 - Corrugating sheet metal, rods or profiles, or bending sheet metal, rods or profiles into wave form into a peculiar profiling shape
• B21D 51/06 - Making hollow objects characterised by the structure of the objects folded objects
• B21D 51/24 - Making hollow objects characterised by the use of the objects high-pressure containers, e.g. boilers, bottles
• B21F 27/12 - Making special types or portions of network by methods or means specially adapted therefor

Abstract

A device for reducing the number of test pins for improving parallelism according to an embodiment of the present invention comprises: one piece of automatic test equipment (ATE) for testing a plurality of devices under test (DUTs); an interface board that accommodates and connects the DUTs to the ATE and is disposed so that the plurality of DUTs share an expected output value of the ATE; and one test module disposed on the interface board and connected to a pair of DUTs among the plurality of DUTs, wherein the test module may compare DUT output values received from the DUT pair with the expected output value of the ATE and signal-process the result of the comparison and transfer same to the ATE.

IPC Classes  ?

• G01R 31/317 - Testing of digital circuits
• G01R 31/3177 - Testing of logic operation, e.g. by logic analysers
• G01R 31/396 - Acquisition or processing of data for testing or for monitoring individual cells or groups of cells within a battery
• G01R 31/01 - Subjecting similar articles in turn to test, e.g. "go/no-go" tests in mass productionTesting objects at points as they pass through a testing station

Abstract

A composition is useful for treating inflammatory diseases, in which hydrophobic manganese oxide is loaded on micelles so as to be stably protected in vivo thereby easily being delivered to a target site. In addition, the hydrophilic and hydrophobic regions of micelles are bonded with a reactive oxygen species (ROS) cleavable linker and decomposed in response to active oxygen species at an inflammatory site, thereby efficiently releasing hydrophobic manganese oxide particles, and released hydrophobic manganese oxide can generate oxygen to change the microenvironment of the target site, thereby improving the effects of physiologically active substances loaded on the micelles.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 9/107 - Emulsions
• A61K 33/32 - ManganeseCompounds thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

A multi-site test apparatus for a system on chip, according to the present invention, may comprise: one automatic test equipment (ATE) for testing a plurality of semiconductor packages (devices under test (DUT)); and a digital-analog conversion unit which is arranged to connect the ATE to the DUTs, compares output values of the plurality of DUTs to an expected output value of the ATE, and converts digital signals, which are the comparison result, into analog signals, wherein the digital-analog conversion unit can include: a logic gate for comparing the output values of the plurality of DUTs to the expected output value of the ATE; a digital-analog conversion circuit for converting, into analog signals, digital signals that are output from the logic gate; and a digital signal processing unit for analyzing a test result by using the converted analog signals.

IPC Classes  ?

• G01R 31/3167 - Testing of combined analog and digital circuits
• H03M 1/00 - Analogue/digital conversionDigital/analogue conversion
• G01R 31/01 - Subjecting similar articles in turn to test, e.g. "go/no-go" tests in mass productionTesting objects at points as they pass through a testing station
• G01R 31/3177 - Testing of logic operation, e.g. by logic analysers
• G01R 19/25 - Arrangements for measuring currents or voltages or for indicating presence or sign thereof using digital measurement techniques
• G01R 19/165 - Indicating that current or voltage is either above or below a predetermined value or within or outside a predetermined range of values
• G01R 31/28 - Testing of electronic circuits, e.g. by signal tracer

Abstract

The present invention relates to a sandwich panel capable of storing an electronic component such as a printed circuit board, and an apparatus for assembling same. The sandwich panel has synclastic deformation characteristics and comprises: a core material manufactured in a truss shape and provided as an area for storing an electronic component; and upper and lower planar materials made of a two-dimensional expandable material and fixed in parallel with each other with the core material interposed therebetween. The sandwich panel comprises a pair of panel members detachably coupled to each other. Each of the pair of panel members comprises upper and lower planar material and a truss element independently provided and fixed therein. The truss element comprises an assemblable truss element having a snap-fit assembly part such that the pair of planar members are detachably coupled via the snap-fit assembly part. In addition, the auxiliary device comprises: a base part having a size corresponding to that of the sandwich panel and having a plurality of vertical columns thereon; and a fence part extending to a predetermined height in the vertical direction along the peripheral edge of the base part. The vertical columns are used to sequentially align the upper and lower panel members above the base part in the inner area of the fence part.

IPC Classes  ?

• B32B 3/12 - Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a discontinuous layer, i.e. apertured or formed of separate pieces of material characterised by a layer of regularly-arranged cells whether integral or formed individually or by conjunction of separate strips, e.g. honeycomb structure
• B32B 7/022 - Mechanical properties
• B32B 38/06 - Embossing

Abstract

Lactobacillus kunkeeiLactobacillus kunkeei NCHBL-003 strain or inactivated cells thereof as an active ingredient for the treatment, prevention, or alleviation of respiratory or inflammatory diseases. The composition effectively suppresses LPS-induced acute lung injury and exhibits anti-inflammatory effects, and thus can be effectively used for treating, preventing, or alleviating respiratory or inflammatory diseases.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics

Abstract

A device for ultra-low latency packet scheduling based on a hardware-implemented mode according to an embodiment of the present invention may comprise: an input interface module that receives packet streams from a plurality of input devices; a packet processing module that processes the packet streams received from the input interface module; a mode management module that changes and sets a mode related to the packet processing of the packet processing module in real time and requests that the packet processing mode changed and set in real time be propagated to other switching devices; an output determination module that sets and outputs the priority of the packets according to the packet processing mode changed and set in real time by the mode management module; an output queue module for storing the packets which had the priority set by the output determination module; a mode propagation module that propagates the corresponding mode to the other switching devices in response to the request from the mode management module; and an output interface module that outputs the packets stored in the output queue module to the corresponding output devices according to the priority.

IPC Classes  ?

• H04L 47/6295 - Queue scheduling characterised by scheduling criteria using multiple queues, one for each individual QoS, connection, flow or priority
• H04L 69/22 - Parsing or analysis of headers
• H04L 47/625 - Queue scheduling characterised by scheduling criteria for service slots or service orders
• H04L 47/283 - Flow controlCongestion control in relation to timing considerations in response to processing delays, e.g. caused by jitter or round trip time [RTT]
• H04L 47/24 - Traffic characterised by specific attributes, e.g. priority or QoS

Abstract

A NOx storage catalyst includes CHA zeolite, a transition metal ion-exchanged in the CHA zeolite, and a rare earth metal that is different the transition metal and is supported on the CHA zeolite. A method for preparing a NOx storage catalyst includes preparing a synthetic mother liquid including a zeolite raw material as a source of silica and alumina, a structure-inducing material, a complexing material, and a solvent, reacting the synthetic mother liquid to prepare a CHA zeolite, and supporting a transition metal and a rare earth metal that is different from the transition metal on the prepared CHA zeolite.

IPC Classes  ?

• B01J 29/76 - Iron group metals or copper
• B01J 23/83 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups with rare earths or actinides
• B01J 29/70 - Crystalline aluminosilicate zeolitesIsomorphous compounds thereof of types characterised by their specific structure not provided for in groups
• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• B01J 35/30 - Catalysts, in general, characterised by their form or physical properties characterised by their physical properties
• C01B 39/48 - Other types characterised by their X-ray diffraction pattern and their defined composition using at least one organic template directing agent
• F01N 3/08 - Exhaust or silencing apparatus having means for purifying, rendering innocuous, or otherwise treating exhaust for rendering innocuous

Abstract

According to various embodiments, an automated test equipment (ATE) for performing a linear test on a high-speed memory comprises a processor, wherein the processor may be configured to: obtain a test pattern program; store, in response to save pattern (SVP) command code, a value of a direction field, a value of a read/write field, and a value of a data field, which are identified from a test pattern of the test pattern program, in a pattern queue register; convert the value of the data field from first data to second data on the basis of a specific table corresponding to features of a device to be tested from among pre-stored data conversion tables; and assign the second data according to a pre-set data assignment order. Various other embodiments may also be possible.

IPC Classes  ?

• G01R 31/3183 - Generation of test inputs, e.g. test vectors, patterns or sequences
• G01R 31/319 - Tester hardware, i.e. output processing circuits
• G01R 31/3181 - Functional testing

Abstract

The present invention is a technology related to an electrode, an electrolyte and a supercapacitor that use a glycerogel, and, more specifically, relates to a glycerogel stretchable electrode, a glycerogel stretchable electrolyte, a glycerogel stretchable supercapacitor comprising both, and a manufacturing method therefor, the electrode, the electrolyte and the supercapacitor using a stretchable glycerogel newly developed so as to have excellent mechanical properties and electrical conductivity and/or ionic conductivity in temperature conditions from an ultra-low temperature of -20°C to a high temperature of 80°C.

IPC Classes  ?

• H01G 11/86 - Processes for the manufacture of hybrid or EDL capacitors, or components thereof specially adapted for electrodes
• H01G 11/48 - Conductive polymers
• H01G 11/24 - Electrodes characterised by structural features of the materials making up or comprised in the electrodes, e.g. form, surface area or porosityElectrodes characterised by the structural features of powders or particles used therefor
• C08J 3/075 - Macromolecular gels
• C08L 29/04 - Polyvinyl alcoholPartially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids
• C08L 25/18 - Homopolymers or copolymers of aromatic monomers containing elements other than carbon and hydrogen
• C08L 65/00 - Compositions of macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chainCompositions of derivatives of such polymers

Abstract

Disclosed is a thermal management medium having the functions of heat exchange, transfer, absorption, or storage and thermal shock absorption, the medium being characterized by comprising: an open porous material having a hydrophilic-treated pore surface; a thin film outer shell attached to the outside of the open porous material and sealing same in a vacuum; and a working fluid filled in the pores of the open porous material, wherein the open porous material simultaneously acts as a transfer medium for both liquid and gaseous working fluids and has a structure in which the internal space partitioned by the thin film outer shell is completely filled. The thermal management medium functions as an ultra-light structural material that can withstand internal vacuum pressure and external loads, and can also perform various thermal management functions related to rapid heat exchange, transfer, absorption, or storage and thermal shock absorption, wherein each of the functions can be controlled autonomously and is resultantly advantageous for reducing the size and weight of a product or has the advantage of making it possible to freely design the external shape of the product.

IPC Classes  ?

• F28D 15/04 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes with tubes having a capillary structure
• F28D 15/02 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes
• F28D 20/00 - Heat storage plants or apparatus in generalRegenerative heat-exchange apparatus not covered by groups or
• H05K 7/20 - Modifications to facilitate cooling, ventilating, or heating
• H01L 23/427 - Cooling by change of state, e.g. use of heat pipes

Abstract

The present invention relates to a technique for producing various kinds of biochemical materials as well as bioethanol by saccharification of fiber wastes and, more specifically, to a method for producing a fiber waste-derived glucose solution and a method for producing bioethanol, sorbitol, and lactic acid by using the solution produced thereby, wherein fiber wastes are sorted into undyed natural fibers, dyed natural fibers, and blended fibers of natural fibers and synthetic resin, and each type of fibers are subjected to efficient pretreatment appropriate for characteristics thereof, thereby improving enzymatic hydrolysis efficiency, followed by efficient fermentation techniques to produce various biochemical materials including lactic acid, sorbitol, terephthalic acid (TPA), and ethylene glycol (EG) as well as bioethanol.

IPC Classes  ?

• C12P 19/02 - Monosaccharides
• C12P 7/06 - Ethanol, i.e. non-beverage
• C12P 7/18 - Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic polyhydric
• C12P 7/56 - Lactic acid
• C07C 29/14 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen-containing functional group of C=O containing groups, e.g. —COOH of a —CHO group
• C07C 31/26 - Hexahydroxylic alcohols

Abstract

The present invention provides a pharmaceutical composition and health functional food for preventing or treating cerebral infarction, the composition comprising micro RNA-382-5P (miR-382-5P). The miR-382-5P is involved in interneuron adhesion, nervous system development, vocal behavior, neurotrophin signaling pathways, dopaminergic synapses, P13K-AKT signaling pathways, and apoptosis. The composition according to the present invention has an excellent effect in reducing the extent or severity of cerebral infarction.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A23L 33/13 - Nucleic acids or derivatives thereof

Abstract

The present invention provides a pharmaceutical composition and health functional food for preventing or treating cerebral infarction, the composition comprising micro RNA-412-5P (miR-412-5P). The miR-382-5P is involved in nervous system development, neurotrophin signaling pathways, Hippo signaling pathways, axon guidance, and Wnt/PCP pathways. The composition according to the present invention has an excellent effect in reducing the extent or severity of cerebral infarction.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A23L 33/13 - Nucleic acids or derivatives thereof

Abstract

An otitis media treatment device is disclosed. The otitis media treatment device of the present invention may comprise: a housing; a light unit which is equipped with a light chamber connected to the housing, and a light source positioned in an inner space formed in the light chamber; a guide frame which is equipped with a guide frame body connected to the light chamber, and a guide frame hole formed in the guide frame body so as to communicate with the inner space of the light chamber; and a light transfer module which is coupled to the guide frame body, is received in the guide frame hole, has one end part thereof received in the light chamber so as to be spaced from the light source so as to face the light source, and has the other end part thereof positioned outside the guide frame.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61B 5/01 - Measuring temperature of body parts
• A61B 1/227 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for ears, i.e. otoscopes
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The present disclosure relates to a security circuit for detecting physical attacks on a system semiconductor. The security circuit includes at least: a shielding layer having a mesh structure composed of a transmission line; a processor configured to determine that a focused ion beam (FIB) circuit editing attack was detected when a difference between predetermined counter output and a first counter output is less than a first reference value; determine that a microprobing attack was detected when a difference between the second counter output and the first counter output exceeds a second reference value; and output an alarm signal when detecting the circuit editing attack or the microprobing attack.

IPC Classes  ?

• G06F 7/04 - Identity comparison, i.e. for like or unlike values
• G06F 21/75 - Protecting specific internal or peripheral components, in which the protection of a component leads to protection of the entire computer to assure secure computing or processing of information by inhibiting the analysis of circuitry or operation, e.g. to counteract reverse engineering
• H03K 19/17768 - Structural details of configuration resources for security

Abstract

The present invention relates to a therapeutic agent of a lipase inhibitor for a wide spectrum of RNA viral infections in humans and animals. More specifically, the lipase inhibitor can be used as a therapeutic agent for influenza A virus infection, bovine coronavirus infection, porcine epidemic diarrhea coronavirus infection, bovine rotavirus infection, porcine reproductive and respiratory syndrome virus infection, and sapoviral infection and furthermore, can be utilized as a therapeutic agent for various RNA viral infections in humans and animals, such as infections with SARS COV-1, MERS-COV, Zika virus, dengue fever virus, and hepatitis A and C viruses.

IPC Classes  ?

• A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
• A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

The present invention relates to: deimmunized flagellin that does not induce the production of flagellin-specific antibodies; and use thereof. In particular, the present invention relates to a flagellin variant in which a major epitope that forms an antibody against flagellin is deleted, the flagellin variant being characterized by, when used as a vaccine adjuvant, not producing antibodies against flagellin while maintaining an excellent immune enhancer effect.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C07K 14/28 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Vibrionaceae (F)

Abstract

The present invention relates to a novel hydroxylase with plastic degradation activity and a method for degrading plastics by using same. As the present invention provides an excellent effect in in degrading plastics into small molecules as well as modifying the structure of plastics, the present invention may be effectively used in industrial fields related to a pretreatment process, etc. for biodegradation or plastic upcycling of waste plastic and microplastics that exist in various environments such as landfills and oceans.

IPC Classes  ?

• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C08J 11/10 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation

Abstract

The present invention relates to a composition for preventing or treating a non-alcoholic fatty liver disease or metabolic syndrome, comprising flagellin fusion proteins and, more specifically, to a composition for preventing or treating a non-alcoholic fatty liver disease or metabolic syndrome, comprising fusion proteins comprising: flagellin, a fragment thereof, or a variant thereof; and an immunoglobulin Fc region.

IPC Classes  ?

• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention provides a novel protein specifically binding to calreticulin and having the scaffold of human fibronectin domain III and a use thereof, wherein the protein can be used for diagnosing cell damage in an early stage to early determine cancer therapy effects and rapidly evaluate in vivo toxicity, thus finding advantageous applications as a candidate material for probes for in vivo diagnosis and treatment of cancer.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 49/00 - Preparations for testing in vivo
• A61K 49/16 - AntibodiesImmunoglobulinsFragments thereof
• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
• A61P 35/00 - Antineoplastic agents
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

Provided are a novel organostannyl silicate compound, a method for preparing the same, a photoresist composition including the organostannyl silicate compound according to the present disclosure, and a method for forming a photoresist pattern using the composition. The organostannyl silicate compound of the present disclosure is industrially very useful, since the compound may implement a photoresist composition having excellent light sensitivity and etching resistance and a high-quality semiconductor device may be manufactured using the composition.

IPC Classes  ?

• C07F 7/22 - Tin compounds
• G03F 7/004 - Photosensitive materials

Abstract

The present invention relates to an attenuated Salmonella gallinarum strain and use thereof. Particularly, the present invention relates to: a novel attenuated Salmonella strain in which all of a gene encoding guanosine tetraphosphate (ppGpp) synthetase, a gene that induces the function of a type III secretion system (T3SS)(ssrAB), and a Gifsy 2prophage gene are deleted; and a composition for treating or diagnosing tumors by using same.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/112 - SalmonellaShigella
• A61K 49/00 - Preparations for testing in vivo
• A61P 35/00 - Antineoplastic agents
• C07K 14/255 - Salmonella (G)
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12R 1/42 - Salmonella

Abstract

In the present invention, actinoflavosides, which are three novel secondary metabolites, have been discovered in a culture solution of two actinomycete strains (JML48 and JMS33) that were isolated from tidal mudflat sediment in Muan, Republic of Korea, and planar structures and stereostructures of the actinoflavosides have been identified through MS, UV and NMR analyses, DQF-COSY experiments and a modified Mosher's method. Actinoflavosides, which are identified novel materials, exhibit antibacterial activity, significantly increase the production of IL-2 and reduce the production of IL-4 in mouse splenocytes, and promote the proliferation of splenocytes, and thus can be used in antibacterial agents and effective treatments for bacterial infectious diseases and cancer or various immune-related diseases.

IPC Classes  ?

• C07H 17/06 - Benzopyran radicals
• A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 31/04 - Antibacterial agents
• A61P 35/00 - Antineoplastic agents
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

The present invention relates to a novel peptide targeting dendritic cells in the body, and a composition which is for treating cancer, and comprises the peptide. Specifically, the present invention relates to a composition for treating or preventing cancer, the composition comprising: a novel peptide targeting dendritic cells in the body; a tumor antigen; and flagellin. In addition, the novel peptide targeting dendritic cells in the body, the tumor antigen, and the flagellin according to the present invention may be linked by a single peptide or included in respective peptides.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids

Abstract

A pharmaceutical composition utilizes a cultured product obtained by differentiating a mesenchymal stem cell into a neuron. The pharmaceutical composition may be used to treat Parkinson's disease. The cultured product exhibits a preventive or therapeutic effect against Parkinson's disease by inhibiting dopaminergic neuron apoptosis by reducing insoluble alpha-synuclein aggregated in the neuron.

IPC Classes  ?

• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• A61P 25/16 - Anti-Parkinson drugs
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/0793 - Neurons

Abstract

The present invention relates to a composition which has the effect of inhibiting osteoclast differentiation and/or generation due to including a specific compound, and thus can exhibit excellent medicinal effects and health functional properties for bone diseases including osteoporosis and the like.

IPC Classes  ?

• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61P 19/00 - Drugs for skeletal disorders
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives

Abstract

The present invention relates to a composition that contains a specific compound that has the effect of inhibiting osteoclast differentiation and/or formation and thus can exhibit excellent pharmacological efficacy and health functionality for bone diseases including osteoporosis, etc.

IPC Classes  ?

• A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
• A61P 19/00 - Drugs for skeletal disorders
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives

Abstract

Disclosed are a ventilation control device and method for managing ventilation inside a livestock barn on the basis of a livestock location. The ventilation control device comprises: an input vector generation unit for generating an input vector representing the coordinates of a livestock location included in image information, when image information taking the image of a livestock barn is inputted; and a ventilation control unit for applying the generated input vector to a pretrained prediction model to predict, among a plurality of operation modes for operating the ventilation device of the livestock barn, an operation mode that would keep the concentration of pollutants contained in the air to the lowest possible level, and controlling the ventilation device in accordance with the predicted operation mode.

IPC Classes  ?

• A01K 1/00 - Housing animalsEquipment therefor
• G06N 3/08 - Learning methods
• G05B 23/02 - Electric testing or monitoring
• H04N 7/18 - Closed-circuit television [CCTV] systems, i.e. systems in which the video signal is not broadcast
• G06Q 50/10 - Services

Abstract

The present invention relates to a microbial electrolysis cell capable of increasing the activity of microbes and, simultaneously, improving a hydrogen production rate. Specifically, the microbial electrolysis cell provided according to one aspect of the present invention comprises: an electrolytic bath including a culture medium for the growth of microbes; an electrode unit including an anode electrode and a cathode electrode positioned to be spaced apart and face each other within the electrolytic bath; a power supply unit electrically connected to the anode electrode and the cathode electrode; and a magnetic field derivative capable of at least forming electromagnetic force on the surface of the cathode electrode.

IPC Classes  ?

• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave
• C12M 1/107 - Apparatus for enzymology or microbiology with means for collecting fermentation gases, e.g. methane
• C12P 3/00 - Preparation of elements or inorganic compounds except carbon dioxide
• C25B 1/04 - Hydrogen or oxygen by electrolysis of water
• C02F 3/00 - Biological treatment of water, waste water, or sewage
• C02F 1/461 - Treatment of water, waste water, or sewage by electrochemical methods by electrolysis

Abstract

The present disclosure relates to a novel microorganism with plastic (polystyrene)-degrading activity and its use, and newly discovered strains of Pseudomonas lini JNU 01 and Acinetobacter johnsonii JNU 01 capable of degrading plastic, especially polystyrene, and has the effect of providing a method for degrading plastic using the same.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• B09B 3/60 - Biochemical treatment, e.g. by using enzymes
• C08J 11/10 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• B09B 101/75 - Plastic waste
• C12R 1/01 - Bacteria or actinomycetales
• C12R 1/38 - Pseudomonas

Abstract

StreptomycesStreptomyces sp. JCK-8055 strain, a composition for plant disease control, containing a culture broth of the strain or an extract therefrom, a preparation method therefor, and a control method using same. It has been found that the composition containing the culture broth of the strain and the antimicrobial active substance isolated therefrom exhibits excellent disease control activity and resistance-inducting activity, and thus can be utilized as an eco-friendly bioagent for pretreatment on plants or as a seed coating agent.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A01N 63/28 - Streptomyces
• A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• A01P 3/00 - Fungicides
• C12R 1/465 - Streptomyces

Abstract

Disclosed are a device and a method for analyzing average surface roughness by extracting a feature from membrane image. The analysis device comprises: an input vector generation unit which generates multiple processed images by processing a membrane image related to a nanofiber when the membrane image is input, groups the multiple generated processed images into an image group, and preprocesses the processed images included in the grouped image group to generate input vectors; and an analysis unit which applies the input vectors included in the image group to a pre-trained prediction model to output average logarithmic surface roughness values, and calculates statistical average surface roughness values of the membrane image by using the multiple output average surface roughness values.

IPC Classes  ?

• G06T 7/40 - Analysis of texture
• G06T 7/13 - Edge detection
• G06V 10/40 - Extraction of image or video features
• G06N 3/0464 - Convolutional networks [CNN, ConvNet]
• G06N 3/08 - Learning methods

Abstract

Lysobacter enzymogenesLysobacter enzymogenes JCK-1421 strain; a composition for controlling plant fungal disease, bacterial disease, or nematode disease, including the strain, a culture product thereof, or an extract thereof; a preparation method for the composition; and a method for controlling plant fungal disease, bacterial disease, or nematode disease using the composition.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A01N 63/20 - BacteriaSubstances produced thereby or obtained therefrom
• A01P 3/00 - Fungicides
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• A01P 5/00 - Nematocides
• C12R 1/01 - Bacteria or actinomycetales

Abstract

Bacillus velezensisBacillus velezensis JCK-7158 strain, a culture solution thereof or an extract thereof; a preparation method therefor; and a method for controlling phytopathogenic fungi. The culture solution of the strain or the extract thereof has extraordinarily excellent anti-fungi activity and induced resistance and has an excellent ability to reduce toxin produced by fungi, and thus can be used in controlling phytopathogenic fungi.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A01N 63/22 - Bacillus
• A01P 3/00 - Fungicides
• C12R 1/07 - Bacillus

Abstract

The present invention relates to a DNA construct including: a gene encoding a flagellin protein; and a gene encoding an immunoenhancer (adjuvant) protein. For effective cancer therapy by selectively killing only cancer cells, an attenuated Salmonella strain according to the present disclosure is designed to produce immunogenic substances in cancer tissue to induce a strong anti-cancer immune response, whereby tumor sizes in metastatic cancers as well as primary cancers can be significantly inhibited. Thus, the strain can be advantageously used in a prophylactic or therapeutic composition for improving survival rates.

IPC Classes  ?

• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/112 - SalmonellaShigella
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

The present invention relates to a pharmaceutical composition for prevention or treatment of glioma, comprising a multiple-epitope peptide, and more specifically to a technique using a multiple-epitope peptide for the use of prevention, alleviation, or treatment of glioma, the multiple-epitope peptide comprising: a MHCI peptide represented by the amino acid sequence of SEQ ID NO: 1; a MHCI peptide represented by the amino acid sequence of SEQ ID NO: 2; and a MHCII peptide represented by the amino acid sequence of SEQ ID NO: 3.

IPC Classes  ?

• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 14/74 - Major histocompatibility complex [MHC]
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/62 - DNA sequences coding for fusion proteins
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

An unscented Kalman filter-based beam tracking system and a method thereof are proposed. The system includes a base station for performing beamforming to an unmanned aerial vehicle, and the base station includes a pre-processing unit for deriving an expected vector value for a movement trajectory of the UAV with a signal received from the UAV and selecting at least one sigma point from the derived expected vector value, a covariance derivation unit for deriving an autocovariance by inputting the selected sigma point to a nonlinear measurement function and deriving a cross-covariance with the derived expected vector value and the derived autocovariance, and a beam estimation unit for deriving a beamforming angle for a future movement trajectory of the UAV by deriving an unscented Kalman filter gain from the derived autocovariance and derived cross-covariance, thereby having effects of a low mean square error, high spectral efficiency, high accuracy of beam tracking.

IPC Classes  ?

• H04B 7/06 - Diversity systemsMulti-antenna systems, i.e. transmission or reception using multiple antennas using two or more spaced independent antennas at the transmitting station
• G01S 5/02 - Position-fixing by co-ordinating two or more direction or position-line determinationsPosition-fixing by co-ordinating two or more distance determinations using radio waves
• H04B 7/185 - Space-based or airborne stations
• H04W 16/28 - Cell structures using beam steering

Abstract

Provided is a bioresorbable stent including a stent substrate including a bioresorbable polymer and a contrast medium containing an iodine component, coated on the stent substrate. Since the stent according to the present invention is absorbed in and removed from the human body after a predetermined time, it has excellent biodegradability since it has improved radiopacity by iodine contrast medium coating, it has a high radiography contrast and is very efficient even when a procedure is performed with real time radiography, and since it has low foreshortening and high flexibility, radial force, and re-coil, it may be useful for insertion into a blood vessel having a small diameter, an acute occlusive lesion, an imminent occlusive lesion, and the like.

IPC Classes  ?

• A61F 2/89 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure the wire-like elements comprising two or more adjacent rings flexibly connected by separate members
• A61L 31/04 - Macromolecular materials
• A61L 31/08 - Materials for coatings
• A61L 31/14 - Materials characterised by their function or physical properties
• A61L 31/18 - Materials at least partially X-ray or laser opaque

Abstract

The present invention is a perovskite metal oxide catalyst substituted with metal ions for reducing carbon deposition, a method for producing the same, and a process for performing a methane reforming reaction using this catalyst. The catalyst is produced in which Ni in ionic form is substituted at a portion of the Ti site of SrTiO3, MgTiO3, CaTiO3, or BaTiO3, which is a multi-component metal oxide having a perovskite structure. Then, various methane reforming reactions (steam-methane reforming, dry reforming of methane, catalytic partial oxidation of methane) may be efficiently and economically performed using this catalyst. The nickel-substituted perovskite metal oxide catalyst has a structure in which Ni2+ is substituted in the perovskite lattice structure. Thus, the metal oxide catalyst has advantages in that carbon deposition thereon does not occur, and thus, the catalyst has a high catalytic stability and may be used for a long time.

IPC Classes  ?

• B01J 23/78 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of the iron group metals or copper combined with metals, oxides or hydroxides provided for in groups with alkali- or alkaline earth metals or beryllium
• B01J 23/00 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group
• B01J 37/04 - Mixing
• B01J 37/08 - Heat treatment
• C01B 3/40 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts characterised by the catalyst

Abstract

The present invention relates to the manufacture and application of flagellin immunopotentiating derivatives with TLR5 activity using an eukaryotic cell expression system. The flagellin derivative according to the present invention has a high immunostimulatory effect and can be used in various vaccine and immunotherapy compositions.

IPC Classes  ?

• C07K 14/28 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Vibrionaceae (F)
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to a chromium-added titanium alloy having stress corrosion resistance and a manufacturing method therefor, the alloy comprising, in weight%, 2.5 to 4.5% of Cr, 5.0 to 5.5% of Al, 3.5 to 3.8% of V, and the balance being Ti and inevitable impurities.

IPC Classes  ?

• C22C 14/00 - Alloys based on titanium
• C22F 1/18 - High-melting or refractory metals or alloys based thereon
• C21D 1/02 - Hardening articles or materials formed by forging or rolling, with no further heating beyond that required for the formation

Abstract

Streptomyces lydicusStreptomyces lydicus JCK-6019 strain having excellent antifungal activity and, at the same time, being capable of inducing resistance in a treated plant; a composition for plant disease control comprising the strain, a culture thereof, or an extract thereof; a preparation method for the composition; and a plant disease control method using the composition.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A01N 63/28 - Streptomyces
• A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
• A01N 27/00 - Biocides, pest repellants or attractants, or plant growth regulators containing hydrocarbons
• A01N 31/06 - Oxygen or sulfur directly attached to a cycloaliphatic ring system
• A01P 3/00 - Fungicides
• C12R 1/465 - Streptomyces

Abstract

Aureobasidium pullulansAureobasidium pullulans AK-10 strain, a composition for reducing drought stress comprising the strain, a culture thereof, or an extract thereof, a method for preparing the composition, and a method for inducing drought stress reduction using the composition.

IPC Classes  ?

• C12N 1/16 - YeastsCulture media therefor
• A01N 63/32 - Yeast
• A01P 21/00 - Plant growth regulators
• A01G 7/06 - Treatment of growing trees or plants, e.g. for preventing decay of wood, for tingeing flowers or wood, for prolonging the life of plants
• C12R 1/645 - Fungi

Abstract

The present invention relates to a tumor-targeting Salmonella gallinarum strain and the use thereof. The tumor-targeting Salmonella gallinarum strain has excellent tumor proliferation inhibitory activity and enables tumor-specific targeting, and thus can be utilized for treatment and imaging of tumors without any side effects.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 49/00 - Preparations for testing in vivo
• A61P 35/00 - Antineoplastic agents
• C12N 1/20 - BacteriaCulture media therefor
• C12N 1/36 - Adaptation or attenuation of cells
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Abstract

An aerosol generation device according to an embodiment may comprise: a body which has a first surface, a second surface opposite to the first surface, and side surfaces between the first and second surfaces, and includes a mouthpiece end disposed at the first surface; an atomization region which is disposed within the body and connected to the mouthpiece end; a storage part which is connected to the atomization region and in which an aerosol-forming substrate is stored; and a surface wave generation part which is connected to the atomization region and generates surface waves, wherein: the surface wave generation part comprises a piezoelectric substrate extending to the atomization region and a converter disposed on the piezoelectric substrate; the converter converts an electrical signal into surface waves; the surface waves are provided to the atomization region; and the converter has a comb pattern shape.

IPC Classes  ?

• A61M 15/00 - Inhalators
• A61M 11/00 - Sprayers or atomisers specially adapted for therapeutic purposes
• A24F 40/05 - Devices without heating means
• A24F 40/10 - Devices using liquid inhalable precursors
• H03H 9/02 - Networks comprising electromechanical or electro-acoustic elementsElectromechanical resonators Details

Abstract

The present invention pertains to a statistical learning system for analyzing the influence of an independent variable, which expands the size of a training set of training data and the number of repetitions and performs statistical analysis of a regression model considering multicollinearity by comprising: a statistical learning module on which a regression analysis model is mounted to perform binary classification on the basis of a cutoff of a dependent variable, wherein a normalization technique for maintaining a plurality of variable features while reducing the size of a training model coefficient, when learning a training data set including information of the independent variable, or a dimension conversion technique for converting a dimension of the independent variable without affecting the dependent variable is applied to the regression analysis model; a cutoff setting module that optimizes a value of the cutoff for each regression analysis model, the value being a reference of the binary classification of the statistical learning module; and a dataset expanding module that amplifies the number of learnings of the training data set by using a cross-validation.

IPC Classes  ?

• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
• G16H 70/00 - ICT specially adapted for the handling or processing of medical references
• G06N 20/20 - Ensemble learning
• G06N 20/00 - Machine learning
• G16H 30/00 - ICT specially adapted for the handling or processing of medical images

Abstract

The present invention relates to a method and a program for predicting the risk of major adverse cardiovascular events after an acute ischemic stroke, and the method and the program, according to the present invention, can accurately predict major adverse cerebro-cardiovascular events (MACCE) in a subject after the onset of symptoms of an acute ischemic stroke and the like.

IPC Classes  ?

• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61B 5/02 - Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
• A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition

Abstract

A system and method of calibrating a camera and a LiDAR sensor through high-resolution conversion of LiDAR data is proposed. The system is included a data reception unit for receiving at least one image data and LiDAR data, which are obtained by photographing a target object, from the respective camera and LiDAR sensor, a feature point extraction unit for extracting feature points of each of the received image data and LiDAR data, a conversion information derivation unit for deriving image conversion information for fusing the feature points of each image data, and deriving LiDAR conversion information for fusing the feature points of each LiDAR data, and a data fusing unit for fusing at least two feature points of the image data, and fusing at least two feature points of the LiDAR data, thereby fusing the fused feature points of the image data and LiDAR data.

IPC Classes  ?

• G01S 7/497 - Means for monitoring or calibrating
• G01S 17/86 - Combinations of lidar systems with systems other than lidar, radar or sonar, e.g. with direction finders

Abstract

A composition for enhancing the growth of a plant may include gelatin having a relatively small diameter so that the composition can be bound or attached to leaves of the plants or the surface of roots thereof. Thus, the growth of the plant treated with the composition may be enhanced.

IPC Classes  ?

• A01N 25/24 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing ingredients to enhance the sticking of the active ingredients
• A01N 25/10 - Macromolecular compounds
• A01P 13/00 - HerbicidesAlgicides
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• C05G 3/40 - Mixtures of one or more fertilisers with additives not having a specifically fertilising activity for affecting fertiliser dosage or release rateMixtures of one or more fertilisers with additives not having a specifically fertilising activity for affecting solubility

Abstract

Pseudomonas fluorescens Pseudomonas fluorescens Pseudomonas fluorescens JNU01 according to the present invention can decompose plastics when cultured in a medium containing plastic, and can therefore be used in a pretreatment process for plastic recycling.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• C08J 11/10 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation
• B09B 3/60 - Biochemical treatment, e.g. by using enzymes
• C12R 1/39 - Pseudomonas fluorescens

Abstract

The present invention relates to an antibacterial, antifungal, or antiseptic composition comprising a Paenibacillus elgi strain having antibacterial and antifungal activity, a culture medium or extract thereof, and a method for preparing same. The culture medium or extract of the Paenibacillus elgi strain of the present invention has antibacterial and antifungal activity on bacteria, fungi, yeast, etc., and can be used as an active ingredient in cosmetics, beauty, food preservatives, and preservatives having excellent antibacterial and antifungal effects, and by controlling the concentration of Pelgipeptin peptide, which is an active ingredient of the culture extract of Paenibacillus elgi, the antibacterial, antiseptic, skin care, and food preservation effects against specific microorganisms can be significantly improved.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A01N 63/20 - BacteriaSubstances produced thereby or obtained therefrom
• A01P 3/00 - Fungicides
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• C12R 1/01 - Bacteria or actinomycetales

Abstract

The present disclosure relates to a plant disease control composition comprising a culture broth of Streptomyces sp. JCK-6141 strain or an extract of the culture broth of the strain, a preparation method therefor and a plant disease control method. The culture broth of the strain or an extract thereof exhibits extremely excellent antimicrobial activity when applied to a causative pathogen of plant disease and thus may be effectively used for plant disease control.

IPC Classes  ?

• A01N 63/28 - Streptomyces
• C12N 1/20 - BacteriaCulture media therefor
• A01P 3/00 - Fungicides
• G01N 30/02 - Column chromatography

Abstract

Disclosed are a composition including a Pseudomonas sp. strain having excellent plastic degradation activity and the use thereof. The Pseudomonas sp. Strain may include Pseudomonas sp. JNU 01 (Accession No: KCTC 14861BP).

IPC Classes  ?

• B09B 3/60 - Biochemical treatment, e.g. by using enzymes
• C12N 1/20 - BacteriaCulture media therefor

Abstract

Disclosed are an electrolyte membrane with excellent durability resulting from the inclusion of a metal-organic framework (MOF), and a membrane-electrode assembly including the same. The electrolyte membrane may include an ionomer; and metal-organic frameworks (MOFs) in which a first metal ion and an organic ligand are coordinated.

IPC Classes  ?

• H01M 8/1046 - Mixtures of at least one polymer and at least one additive
• H01M 8/1004 - Fuel cells with solid electrolytes characterised by membrane-electrode assemblies [MEA]
• H01M 8/1039 - Polymeric electrolyte materials halogenated, e.g. sulfonated polyvinylidene fluorides
• H01M 8/1032 - Polymeric electrolyte materials characterised by the chemical structure of the main chain of the ion-conducting polymer having sulfur, e.g. sulfonated-polyethersulfones [S-PES]
• H01M 8/1027 - Polymeric electrolyte materials characterised by the chemical structure of the main chain of the ion-conducting polymer having carbon, oxygen and other atoms, e.g. sulfonated polyethersulfones [S-PES]
• H01M 8/1072 - Polymeric electrolyte materials characterised by the manufacturing processes by chemical reactions, e.g. insitu polymerisation or insitu crosslinking
• C07F 7/22 - Tin compounds

Abstract

22) is inhibited by the chloride ion adsorbent while producing hydrogen without treating seawater to freshwater. In the absence of the chloride ion adsorbent, otherwise, a large amount of chloride ions (Cl-) will be oxidized during electrolysis due to NaCl dissolved in a large amount in seawater.

IPC Classes  ?

• B01J 20/10 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
• B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
• B01J 20/30 - Processes for preparing, regenerating or reactivating
• C25B 1/04 - Hydrogen or oxygen by electrolysis of water

Abstract

The present invention relates to host cells expressing monomeric streptavidin. The host cells according to the present invention may express streptavidin in vivo, making it possible to visualize and monitor in real time the biodistribution of cancer tissue, pre-targeted by the host cell, with a biotinylated diagnostic agent, as well as to increase the cancer-targeting efficiency of biotinylated anticancer drugs.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 49/00 - Preparations for testing in vivo
• A61K 47/66 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
• C12N 1/20 - BacteriaCulture media therefor
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli

Abstract

The present invention relates to a monomeric streptavidin-expressing gene construct and a host cell into which a recombinant vector comprising the gene construct has been introduced. The gene construct according to the present invention, after injected in vivo through a strain, may express streptavidin, thereby making it possible not only to monitor in real time the location of the strain or a cancer tissue pre-targeted by the strain by using a biotinylated diagnostic agent, but also to increase the cancer targeting efficiency of a biotinylated anticancer agent.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Abstract

The present invention relates to a pharmaceutical composition for preventing, improving, or treating renal fibrosis, and more specifically, to a pharmaceutical composition and a health functional food for preventing, improving, or treating renal fibrosis comprising one or more active ingredients, wherein it was confirmed that β-elemene and Z-guggulsterone individually or in cooperation with each other inhibit renal fibrosis in renal tubules and renal interstitial fibroblasts, and the present invention was developed using novel uses of β-elemene and Z-guggulsterone.

IPC Classes  ?

• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives

Abstract

Lactobacillus plantarumLactobacillus plantarum NCHBL-004 strain or a culture medium thereof, and the composition not only inhibits adipocyte differentiation and inhibits weight gain, but also exhibits a blood sugar lowering effect, and can thus be effectively used for preventing, treating, or improving metabolic diseases.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• C12N 1/20 - BacteriaCulture media therefor

Abstract

Lactobacillus kunkeeiLactobacillus kunkeei NCHBL-003 strain or a culture medium thereof, wherein the composition not only inhibits adipocyte differentiation and weight gain, but also has a blood sugar lowering effect, thus being able to be effectively used in preventing, treating, or improving metabolic diseases.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 3/00 - Drugs for disorders of the metabolism
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

In a method for preparing lithium hydroxide, a first mixture of lithium sulfate (Li2SO4) and barium hydroxide (Ba(OH)2) is prepared, a second mixture that is converted into insoluble lithium sulfate (BaSO4) and soluble lithium hydroxide (LiOH) is prepared by roasting the first mixture, the second mixture is dissolved to precipitate the insoluble barium sulfate (BaSO4), the precipitated barium sulfate (BaSO4) is separated by solid-liquid separation, and the solution from which the barium sulfate (BaSO4) is separated is evaporated to obtain lithium hydroxide (LiOH).

IPC Classes  ?

• C01D 15/02 - OxidesHydroxides

Abstract

A wireless charging device is proposed. The wireless charging device may maximize charging efficiency improvement and heat generation reduction effect by appropriately arranging a second magnetic body on a first magnetic body, resulting in an offset of a magnetic flux linkage occurring inside an aluminum shield due to a magnetic field having passed through the first magnetic body.

IPC Classes  ?

• H02J 50/70 - Circuit arrangements or systems for wireless supply or distribution of electric power involving the reduction of electric, magnetic or electromagnetic leakage fields
• H02J 50/10 - Circuit arrangements or systems for wireless supply or distribution of electric power using inductive coupling
• H02J 50/00 - Circuit arrangements or systems for wireless supply or distribution of electric power
• H01F 27/36 - Electric or magnetic shields or screens

Abstract

Lactobacillussakeisakei) CVL-001. Mesenchymal stem cells treated with the strain were confirmed to exhibit suppressed T cell proliferation and increased production of interleukin-10 (IL-10), and thus, the pharmaceutical composition can be effectively used as a composition for preventing, treating or ameliorating inflammatory diseases.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
• A61Q 19/00 - Preparations for care of the skin
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis

Abstract

The invention relates to a spherical electromagnetic actuator. The spherical electromagnetic actuator including a spherical permanent magnet having a center region, a housing comprising a chamber enclosing the spherical magnet and having an inlet for receiving a fluid. The actuator further including three electromagnetic coil assemblies with each coil assembly having at least one coil and a virtual symmetry axis, and wherein the three electromagnetic coil assemblies are arranged such that the three respective symmetry axes intersect at a center region the spherical permanent magnet. The housing is arranged such that in operation the fluid causes the spherical magnet to levitate. And, in operation, the three electromagnetic coil assemblies provide a superpositioned magnetic field manipulating the orientation of the spherical magnet. The invention further relates to a method for controlling the magnetic field of at least one spherical magnetic actuator.

IPC Classes  ?

• H02K 26/00 - Machines adapted to function as torque motors, i.e. to exert a torque when stalled
• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• H02K 41/03 - Synchronous motorsMotors moving step by stepReluctance motors
• A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
• H02K 11/215 - Magnetic effect devices, e.g. Hall-effect or magneto-resistive elements
• H02K 11/25 - Devices for sensing temperature, or actuated thereby
• H02K 11/27 - Devices for sensing current, or actuated thereby
• H02K 11/30 - Structural association with control circuits or drive circuits

Abstract

The present invention relates to a design and encoding method and device for a low-density parity-check code. The design and encoding method for a low-density parity-check code, according to one embodiment of the present invention, may comprise the steps of: (a) generating a proto-matrix for a protograph-based raptor-like (PBRL) low-density parity-check (LDPC) code; (b) adding at least one edge to the proto-matrix; and (c) performing encoding using the proto-matrix to which the at least one edge has been added, thereby generating a codeword.

IPC Classes  ?

• H03M 13/11 - Error detection or forward error correction by redundancy in data representation, i.e. code words containing more digits than the source words using block codes, i.e. a predetermined number of check bits joined to a predetermined number of information bits using multiple parity bits
• H03M 13/01 - Coding theory basic assumptionsCoding boundsError probability evaluation methodsChannel modelsSimulation or testing of codes
• H03M 13/00 - Coding, decoding or code conversion, for error detection or error correctionCoding theory basic assumptionsCoding boundsError probability evaluation methodsChannel modelsSimulation or testing of codes
• H04L 1/00 - Arrangements for detecting or preventing errors in the information received
• H04L 1/20 - Arrangements for detecting or preventing errors in the information received using signal-quality detector

Abstract

Provided is a recombinant expression vector containing a hybrid signal sequence and a method for secretory production of a human insulin-like growth factor-1 using the same. A heterologous signal sequence that significantly improves secretory expression of the human insulin-like growth factor-1 (hIGF1) is introduced into Komagataella phaffii, which is a unicellular eukaryotic cell, used as a host, such that various types of available signal sequences may be secured, and significantly improved secretion productivity may be achieved.

IPC Classes  ?

• C12N 15/62 - DNA sequences coding for fusion proteins
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
• C12N 15/80 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi
• C07K 14/475 - Growth factorsGrowth regulators

Abstract

The present invention relates to a glycerogel and a method for producing same, and more specifically, to: an extremotolerant glycerogel that exhibits excellent long-term stability at -50°C to 80°C, while maintaining the structural and functional properties of a hydrogel; a method for manufacturing same; and an applied product containing same.

IPC Classes  ?

• C08J 3/075 - Macromolecular gels

Abstract

Disclosed are an osteosynthesis plate structure and a method for manufacturing the osteosynthesis plate structure. The present invention comprises a first carbon structure in which a plurality of carbon fibers are arranged in parallel with each other and a second carbon structure which is stacked on the first carbon structure and in which a plurality of carbon fibers are arranged in parallel with each other, wherein the direction in which the plurality of carbon fibers are arranged in the second carbon structure and the direction in which the plurality of carbon fibers are arranged in the first carbon structure cross each other at a crossing angle of 30 degrees to 40 degrees. According to the present invention, by manufacturing an osteosynthesis plate structure as a carbon fiber structure, medical staff can obtain a clean photographing image (artifact-free image) without a light reflection effect in case that X-ray photographing is performed at a procedure portion.

IPC Classes  ?

• A61B 17/80 - Cortical plates
• B32B 5/26 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by the presence of two or more layers which comprise fibres, filaments, granules, or powder, or are foamed or specifically porous one layer being a fibrous or filamentary layer another layer also being fibrous or filamentary
• B32B 7/03 - Layered products characterised by the relation between layers Layered products characterised by the relative orientation of features between layers, or by the relative values of a measurable parameter between layers, i.e. products comprising layers having different physical, chemical or physicochemical properties Layered products characterised by the interconnection of layers with respect to the orientation of features
• B32B 38/00 - Ancillary operations in connection with laminating processes
• A61B 17/00 - Surgical instruments, devices or methods

Abstract

Disclosed are a conductive polymer substrate and a method for manufacturing the same, wherein the conductive polymer substrate has improved cell alignment, maturity, adhesion, and connectivity by having nanopatterns on a surface thereof while having electric conductivity through embedded silver nanowires (AgNWs).

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C08K 7/06 - Elements
• C08J 7/044 - Forming conductive coatingsForming coatings having anti-static properties

Abstract

The present invention relates to a Salmonella strain that selectively acts on cancer for the treatment of cancer, and a composition for preventing or treating cancer containing the same. In particular, the Salmonella strain according to the present invention has a tumor-suppressing effect, but has a significantly low viability in normal organs, and thus may have a significant anticancer effect compared to conventional inventions.

IPC Classes  ?

• A61K 35/74 - Bacteria
• C07K 14/24 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
• A61P 35/00 - Antineoplastic agents
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Provided is a method of preparing a circular permutation (CP)-based functional recombinant human-derived fibroblast growth factor 7 and a use thereof. The fibroblast growth factor 7 to which a circular permutation is applied (CP-hFGF7115-114) is independently expressed in a host cell, such that soluble overexpression of the fibroblast growth factor 7 may be induced without causing problems according to the related art, such as lower expression level and stability compared to those of a wild-type hFGF7 protein and amino acid changes in a process of removing a fusion tag.

IPC Classes  ?

• C07K 14/50 - Fibroblast growth factor [FGF]
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli

Abstract

The present invention relates to a composition for treating colitis, comprising a flagellin and immunoglobulin Fc fusion protein and, more specifically, to a composition for treating colitis, which is a fusion protein comprising flagellin and a variant of human IgG4 Fc, wherein the human IgG4 Fc variant has a mutation that prevents Fab-arm exchange.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A23L 33/195 - Proteins from microorganisms

Abstract

The present invention relates to a composition comprising a flagellin and immunoglobulin Fc fusion protein for the treatment of liver disease or metabolic syndrome and, more specifically, concerns a composition comprising a fusion protein including flagellin and a variant of human IgG4 Fc for the treatment of liver disease or metabolic syndrome, wherein the variant of human IgG4 Fc possesses a mutation that prevents Fab arm exchange.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/00 - Drugs for disorders of the metabolism
• A23L 33/195 - Proteins from microorganisms

Abstract

Salicornia europaeaSalicornia europaea) extract or a fraction thereof for the prevention, treatment, or alleviation of bone diseases. Dicaffeoylquinic acid (DCQA) fractionated from the hot-water extract of glasswort suppresses macrophage-induced differentiation into osteoclasts and inhibits the expression of differentiation-related genes, and thus can be advantageously utilized for the prevention, treatment, or alleviation of bone diseases.

IPC Classes  ?

• A61K 36/21 - Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives

Abstract

A catheter-type ultrasound endoscope according to an embodiment of the present invention includes an ultrasound module for acquiring an ultrasound image, and a biopsy needle, wherein the ultrasound module includes a pMUT module and an ASIC signal processing circuit, and the ASIC signal processing circuit uses CMOS-MEMS technology. This steerable catheter-type ultrasound endoscope capable of performing tissue biopsies according to the present invention obtains ultrasound images from representative digestive organs, such as the bile duct and the pancreatic duct, through the miniaturization of the ultrasound module, and performs a biopsy while the ultrasound images are observed in real time, and thus can improve the accuracy of diagnosis.

IPC Classes  ?

• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• A61B 10/04 - Endoscopic instruments, e.g. catheter-type instruments

Abstract

in vivoin vivo therapeutic anticancer effects that exceed that of lenalidomide, which is a commercially available immunomodulatory agent widely used in the treatment of multiple myeloma and myelodysplastic syndrome. In addition, as the compound of the present invention exhibits a remarkable synergistic effect when administered in combination with thalidomide or its analogue, lenalidomide, the compound can be effectively used as an effective therapeutic agent or therapeutic adjuvant composition for multiple myeloma which is an intractable disease.

IPC Classes  ?

• C07C 49/84 - Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
• C07C 49/80 - Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
• C07D 311/28 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
• C07D 307/46 - Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
• C07D 333/16 - Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
• C07D 215/04 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
• C07D 307/80 - Radicals substituted by oxygen atoms
• C07D 407/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• A61K 31/353 - 3,4-Dihydrobenzopyrans, e.g. chroman, catechin

Abstract

The present invention relates to a novel fusion protein in which a monobody specifically binding to a tumor antigen is linked to L-asparaginase for more efficient solid cancer treatment, and a use thereof, and specifically, to a novel asparaginase-based anticancer agent that targets a tumor antigen with enhanced efficiency of drug delivery to tumor tissue, the anticancer agent being a fusion protein in which a calreticulin-specific binding peptide is inserted into at least one of a BC loop or a FG loop of human fibronectin domain III (Fn3), and L-asparaginase is linked to the C-terminus of a recombinant monobody specifically binding to calreticulin.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 38/50 - Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
• A61P 35/00 - Antineoplastic agents

Abstract

pPLAⅡηpPLAⅡηpPLAⅡη gene, so that the gene of the present invention can be advantageously applied as a strategy for rapidly constructing breeding materials of pure line with fixed traits.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• A01H 1/08 - Methods or apparatus for producing changes in chromosome number
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 9/22 - Ribonucleases

Abstract

The present invention relates to a method that allows, from lithium secondary battery waste material powder, removal of impurities, such as iron and aluminum, by means of a solvent extraction technique and the like, and recovery of valuable metals, such as highly concentrated manganese, cobalt, nickel, and lithium, by means of selective recovery.

IPC Classes  ?

• C22B 3/08 - Sulfuric acid
• C22B 26/12 - Obtaining lithium
• C22B 47/00 - Obtaining manganese
• C22B 3/00 - Extraction of metal compounds from ores or concentrates by wet processes

Abstract

The present invention relates to a method for recovering, at a high level of purity, valuable metals contained in waste product powder by selectively removing impurities therefrom by means of leaching, purification, and solvent extraction in order to reuse the waste product, the method allowing removal of impurities such as iron, aluminum, and manganese, and recovery of highly pure valuable metals, such as zinc and copper, by means of selective recovery.

IPC Classes  ?

• C22B 3/08 - Sulfuric acid
• C22B 15/00 - Obtaining copper

Abstract

A user verifying method comprises: receiving an enrollment request signal including biometric information for enrollment from a user terminal; extracting feature information from the biometric information; embedding the feature information extracted from the biometric information; generating a projection parameter and a decision hyperplane parameter based on the embedding result; storing the projection parameter and the decision hyperplane parameter; generating a first template by applying a cryptographic hashing function to a pre-generated first key; receiving a verification request signal including biometric information from the user terminal; extracting feature information from the biometric information; embedding the feature information extracted from the biometric information; generating a second key corresponding to the first key based on the embedding result; generating a second template by applying the cryptographic hashing function to the second key; comparing the first template with the second template; and completing user verification based on the comparison result.

IPC Classes  ?

• H04L 9/32 - Arrangements for secret or secure communicationsNetwork security protocols including means for verifying the identity or authority of a user of the system
• G06N 3/02 - Neural networks
• G06V 40/50 - Maintenance of biometric data or enrolment thereof
• G06N 5/01 - Dynamic search techniquesHeuristicsDynamic treesBranch-and-bound

Abstract

An electronic device, according to one embodiment, comprises: a user interface; a communication unit that communicates with at least one outdoor unit and a plurality of indoor units connected to the at least one outdoor unit; and at least one processor that controls the user interface to determine a heat exchanger having a contamination level equal to or greater than a preset contamination level from among a heat exchanger of the at least one outdoor unit and a heat exchanger of the plurality of indoor units, on the basis of an output of a neural network for operation data received from each of the at least one outdoor unit and the plurality of indoor units, determine a cleaning cycle of the determined heat exchanger on the basis of the energy increase rate of the determined heat exchanger, and output the determined cleaning cycle.

IPC Classes  ?

• F24F 11/49 - Control or safety arrangements for purposes related to the operation of the system, e.g. for safety or monitoring ensuring correct operation, e.g. by trial operation or configuration checks
• F24F 11/46 - Improving electric energy efficiency or saving
• F24F 11/64 - Electronic processing using pre-stored data
• F24F 11/52 - Indication arrangements, e.g. displays
• G06N 3/02 - Neural networks
• F24F 140/12 - Heat-exchange fluid pressure
• F24F 140/20 - Heat-exchange fluid temperature
• F24F 140/50 - Load

Abstract

Provided is an electronic device includes a user interface; a communication module configured to perform communication with at least one outdoor unit and a plurality of indoor units connected to the at least one outdoor unit; and a processor configured to determine a heat exchanger with a contamination level equal to or higher than a preset contamination level among a heat exchanger of the at least one outdoor unit and heat exchangers of the plurality of indoor units based on an output from a neural network for operation data received from each of the at least one outdoor unit and the plurality of indoor units, determine a cleaning period of the determined heat exchanger based on a rate of increase in energy of the determined heat exchanger, and control the user interface to output information indicating the determined cleaning period, wherein the neural network is trained with operation data varying by contamination level of a heat exchanger.

IPC Classes  ?

• F24F 11/65 - Electronic processing for selecting an operating mode
• F24F 11/32 - Responding to malfunctions or emergencies
• F24F 11/52 - Indication arrangements, e.g. displays
• F28G 15/00 - CLEANING OF INTERNAL OR EXTERNAL SURFACES OF HEAT-EXCHANGE OR HEAT-TRANSFER CONDUITS, e.g. WATER TUBES OF BOILERS Details

Abstract

The present invention relates to a peptide that inhibits the formation of a KITENIN dimer, and a use for same, wherein the peptide of the present invention comprises an amino acid sequence represented by SEQ ID NO: 3, and inhibits the formation of a KITENIN dimer, and thus exhibits the benefits of inhibiting cancer oncogenicity, invasiveness and metastasis.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C12N 15/62 - DNA sequences coding for fusion proteins
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a method for preparing lithium hydroxide and, more specifically, to a method for preparing lithium hydroxide by using lithium sulfate and barium oxide, wherein the method is economically beneficial through a simple process, compared with conventional art, by using a low-purity lithium sulfate solution, provides improved energy efficiency, and causes no waste generation, thereby enabling economical production of lithium hydroxide.

IPC Classes  ?

• C01D 15/02 - OxidesHydroxides

Abstract

The present invention relates to a method for preparing primary amides from tertiary or secondary amides substituted with various alkyl groups through a transamidation reaction without a metal catalyst in room-temperature conditions by adding ammonium carbonate ((NH4)2CO3), wherein the method is eco-friendly since various secondary and tertiary amides that are not toxic or corrosive are used as starting materials and ammonium carbonate ((NH4)2CO3) that is neither a strong acid nor a strong base is used, and the method is economical since various primary amides can be synthesized with an excellent yield at room temperature without a metal catalyst.

IPC Classes  ?

• C07C 231/08 - Preparation of carboxylic acid amides from amides by reaction at nitrogen atoms of carboxamide groups

Abstract

A personal information security system and a method thereof ensuring irreversibility and similarity are proposed. According to specific exemplary embodiments of the present technology, the personal information security system includes a feature vector extraction unit for extracting a feature vector from user modality information, an Absolute Value Equations Transform (AVET) unit for performing absolute value equations transform on the feature vector, and a transformed-template generation unit for generating a transformed template (TT) from which the feature vector is unable to be predicted reversely from a result of the AVET.

IPC Classes  ?

• G06F 21/57 - Certifying or maintaining trusted computer platforms, e.g. secure boots or power-downs, version controls, system software checks, secure updates or assessing vulnerabilities
• G06F 21/62 - Protecting access to data via a platform, e.g. using keys or access control rules
• G06F 21/60 - Protecting data

Abstract

The present invention relates to a method for constructing an inner ear organoid using a micro-well plate. Using the method of the present invention, cell aggregates for construction of an inner ear organoid can be easily formed, and uniform and mature inner ear organoids can be constructed using the specific initial cell number control method and growth factor treatment method of the present invention and can be used for inner ear disease modeling and drug screening.

IPC Classes  ?

• C12N 5/0793 - Neurons
• C12M 1/32 - Inoculator or sampler multiple field or continuous type

Abstract

The present invention relates to a composition for preventing or treating inflammatory diseases, comprising a Lactobacillus sakei CVL-001 strain. The composition activates NOD2, which is an inflammation regulator, and exhibits the effects of inhibiting weight loss and improving clinical activity scores (disease activity index; DAI) in an animal model in which ulcerative colitis is induced, and thus the present invention can be effectively used in the prevention, treatment or alleviation of inflammatory diseases.

IPC Classes  ?

• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]